BRIDGEWATER, NEW JERSEY, May 04, 2026
Insmed Incorporated has announced the presentation of multiple clinical and real-world data sets across its respiratory portfolio at the American Thoracic Society (ATS) International Conference 2026, including late-breaking Phase 3b ENCORE study results for ARIKAYCE® (amikacin liposome inhalation suspension). The data highlight the potential of ARIKAYCE to be used earlier in the treatment pathway for patients with Mycobacterium avium complex (MAC) lung disease, a serious and often difficult-to-treat pulmonary condition. In addition to ARIKAYCE findings, Insmed will present six abstracts spanning its pipeline and approved therapies, reinforcing its leadership in respiratory disease innovation and precision medicine.
Phase 3b ENCORE Study Highlights ARIKAYCE Potential
The ENCORE Phase 3b study evaluates ARIKAYCE in combination with a standard multidrug regimen compared to placebo in adults with newly diagnosed MAC lung infection, aiming to assess both efficacy and safety outcomes. ARIKAYCE is a once-daily inhaled formulation of amikacin, delivered using proprietary liposomal technology that enables targeted drug delivery directly to the lungs, where the infection resides.
This approach allows the antibiotic to be taken up by lung macrophages, improving localized therapeutic action while minimizing systemic exposure and associated toxicity. The late-breaking data presentation underscores the potential for ARIKAYCE to expand beyond its current use in refractory cases, potentially transforming treatment paradigms for MAC lung disease and improving outcomes for patients with limited options.
Broader Respiratory Pipeline Demonstrates Clinical Depth
Advertisement
Beyond ARIKAYCE, Insmed’s presentations at ATS 2026 include data from its BRINSUPRI® (brensocatib) program, a first-in-class oral inhibitor of dipeptidyl peptidase 1 (DPP1) approved for non-cystic fibrosis bronchiectasis (NCFB), as well as findings from a pharmacokinetic study of treprostinil palmitil inhalation powder (TPIP), an investigational therapy for pulmonary arterial hypertension (PAH) and related conditions.
Additional analyses highlight the burden of bronchiectasis and pulmonary hypertension associated with interstitial lung disease (PH-ILD), emphasizing the need for innovative and patient-focused treatment strategies. The company also announced support for a landmark quality initiative led by the American Thoracic Society, aimed at improving the diagnosis and management of bronchiectasis across the United States, addressing widespread underdiagnosis and delayed treatment.
Advancing Respiratory Innovation and Clinical Excellence
The breadth of data presented at ATS 2026 reflects Insmed’s commitment to advancing first- and best-in-class therapies for rare and serious pulmonary diseases, where unmet medical need remains high.
From a GxP perspective, the ENCORE and ASPEN trials, along with associated studies, are conducted in compliance with Good Clinical Practice (GCP) standards, ensuring data integrity, patient safety, and regulatory rigor. Respiratory diseases such as MAC lung infection, bronchiectasis, and pulmonary hypertension continue to pose significant clinical challenges, often requiring long-term, complex treatment regimens. By leveraging innovative drug delivery systems, targeted mechanisms of action, and robust clinical research, Insmed is positioned to reshape treatment standards and improve patient outcomes.
The company’s integrated approach, combining clinical development, real-world evidence, and collaborative initiatives, underscores its role as a leader in respiratory therapeutics and biopharmaceutical innovation. As the industry increasingly focuses on precision medicine and targeted delivery technologies, Insmed’s portfolio demonstrates the potential to deliver transformative therapies that address critical gaps in respiratory care worldwide.
Source: Insmed press release
